BOOSTER SHOT
SEC asks J&J to monitor adverse events closely for next three months
SEC asks J&J to submit interim safety data after 28 days
J&J had expanded clinical trials of two-dose regimen to adolescents in
April globally Company is testing a two-dose regimen globally